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Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
disorder, due to the loss of function of the SMN1 gene. The first treatment for the condition, 
recently approved, is based on the reduction of exon 7 skipping in mRNAs produced by a highly 
homologous gene (SMN2).  The primary objective of the present study was to evaluate the 
applicability of SMN dosage in blood, as biomarker for SMA, and the safety of oral salbutamol, a 
beta-2 adrenergic agonist modulating SMN2 levels.  
Methods: We have performed a 1-year multicenter, double-blind, placebo-controlled study with 
salbutamol in forty-five SMA adult patients. Patients assumed 4mg of salbutamol or placebo/3 
times a day. Molecular tests were SMN2 copy number, SMN transcript and protein levels. We 
have also explored the clinical effect, by the outcome measures available at the time of study 
design. 
Results: Thirty-six patients completed the study. Salbutamol was safe and well tolerated.  We 
observed a significant and progressive increase in SMN2 full-length levels in peripheral blood of 
the salbutamol-treated patients (p<0.00001). The exploratory analysis of motor function showed 
an improvement in most patients. 
Conclusions: Our data demonstrate safety and molecular efficacy of salbutamol. We provide the 
first longitudinal evaluation of SMN levels (both transcripts and protein) in placebo and in 
response to a compound modulating SMN levels: SMN transcript dosage in peripheral blood is  
reliable and may be used as pharmacodynamic marker in clinical trials with systemic compounds 
modifying SMN2 expression.  
Trial registration: EudraCT no.2007-001088-32 






Type I-III spinal muscular atrophies (SMA) are autosomal recessive conditions, caused by the 
loss of function of the survival motor neuron (SMN1) gene, and characterized by the 
degeneration of the lower motor neuron.[1] Irrespective of the phenotypic severity, both SMN1 
copies are absent in about 95% of patients, while subtle pathogenic variants are relatively 
uncommon (2-3% of cases).[2] In patients, reduced amounts of the SMN protein are produced by 
SMN2, a nearly identical copy gene. SMN2 is present in variable copy number in patients, 
generally two-four, being higher SMN2 copies grossly related to milder phenotypes.[3,4] SMN2 
genes mainly produce mRNAs lacking exon 7 (SMN-del7), due to an alternative splicing, that 
give rise to an unstable protein that is rapidly degraded.[5] Nusinersen (Spinraza®), an antisense 
oligonucleotide based therapeutic approach with intrathecal administration, has been recently 
approved by FDA and EMA as the first effective treatment in children with SMA.[6,7] Further, a 
number of human trials with different therapeutic approaches are in the pipeline. The most are 
aimed at increasing the production of the SMN protein from SMN2, or at providing SMN1 by 
gene therapy.[8,9]             
In the past, beta-2 adrenoceptor agonists have been evaluated as possible candidates to the 
treatment of SMA: in two small open pilot trials of SMA type III and/or SMA type II children, 
albuterol/salbutamol determined a clinical improvement of patients;[10,11] we have shown that 
the compound increases SMN levels both in vitro (in fibroblast cultures of patients[12]) and in 
vivo (in a small open label study[13]).  
The widest use of salbutamol has been for over thirty years in the treatment of asthma. 
Consequently, the pharmacodynamics of the compound has been extensively studied, including 
genetic factors predisposing to the receptor desensitization. For example, the lack of response to  
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beta2-adrenoceptor agonists in asthmatic patients has been reported to occur more frequently in 
the presence of the Gly allele of the p.Arg16Gly variant, a common polymorphism in the 
adrenoceptor beta 2 gene [ADRB2, rs1042713].[14] 
In this study, we report on the results of a randomized, double-blind, placebo-controlled trial of 
salbutamol in a group of SMA type III adult patients. The primary aims were a) to assess safety 
and tolerability of orally administered high dosage of salbutamol, b) to verify its efficacy in 
increasing SMN levels in peripheral leukocytes, and c) to confirm reliability and applicability of 
SMN2 product dosage in peripheral blood [SMN2-full length (SMN2-fl), SMN-del7, SMN2-total 
transcripts (SMN2-tot)] as a response biomarker/pharmacodynamic markers for SMA. Additional 
objectives were to explore the potential benefit of the drug in improving the motor function of 





Study design and participants 
We designed a multi-centric, 12 months, prospective, randomized, placebo-controlled, double 
blind, phase IIb trial of salbutamol in type III SMA adults. The primary endpoint of the study 
was to verify safety and tolerability of salbutamol and the molecular efficacy of the compound 
on SMN2 gene expression. The exploratory evaluation of the clinical outcome was also 
performed. 
Inclusion criteria were: adult male or female type III SMA out-patients with molecular 
confirmation of the diagnosis, ability to understand and provide an informed consent, and to 
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perform the evaluation tests. Exclusion criteria were: presence of respiratory failure, asthma, 
cardiovascular, hepatic or renal disorders, convulsive disorders, hyperthyroidism, diabetes 
mellitus; concomitant treatment with drugs known to interfere with salbutamol; use of drugs 
known to modulate SMN2 gene expression, within 6 months before starting the study; pregnancy 
or lactation; subjects who have participated in clinical trials within three months prior to 
screening.  
After screening at the baseline visit (V0), patients started oral treatment with salbutamol or 
placebo. The scheme of titration was: 4 mg once-a-day for two weeks, 4 mg twice-a-day for the 
following week, 4 mg three times-a-day for the whole duration of the study.  
After V0, patients were evaluated at one (V1), three (V2), six (V3), and twelve months (V4) of 
full dosage of salbutamol/placebo.  
 
Safety assessment 
Safety of salbutamol was evaluated by the following laboratory and cardiologic assessments: 
blood count, electrolytes, liver and kidney function evaluation, plasma glucose, serum total 
creatine kinase (CK), and urine analysis (each visit); standard-ECG (each visit), Holter-ECG and 
blood pressure 24-hour recording (V0, V1, V3, and V4),  and echocardiogram (V0, and V4).  




After the screening visit and the evaluation of inclusion/exclusion criteria of each patient, every 
Centre required randomization to the Research and Development Office (RDO) of the Institute 
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“Carlo Besta”, the coordinating Centre, by emailing through the electronic CRF.  The RDO 
balanced the randomization, assigned a code to each patient, and requested to the Doppel 
Industry (Rozzano, Milano, Italy) to send the assigned treatment to the recruiting Centre. Patient 
randomization (1:1) was performed per blocks of 6 consecutive numbers (each block contained 
three salbutamol and three placebo treatments). One or more treatment blocks were assigned to 
each Clinical Centre.  
 
Molecular studies 
Molecular studies were performed on peripheral blood (sampled at V0, V2, V3, and V4), and 
were: SMN2-fl, SMN-del7, total SMN2 (SMN2-fl plus SMN-del7, SMN2-tot), GAPDH (used as 
positive control) transcript levels by absolute real time PCR.[15] Molecular responders were 
defined for increases in SMN2 transcript levels above the experimental variation. “Early 
molecular responders” identifies patients who responded at the molecular levels at V2; “late 
molecular responders” did not respond to the treatment at V2. SMN protein levels were assessed 
at V0, V2, and V3 by ELISA assay commercially available (Enzo Life Science).[16] 
Out of the study protocol, we investigated the pharmacodynamics of salbutamol by evaluating 
the variation of SMN2 transcript levels in response to a single dose of 4mg, in two further type 
III naïve patients. We performed blood samplings at the following time points: 30 min before 
salbutamol administration (T-1), at the assumption (T0), after 30 min (T1), and one (T2), two 
(T3), and four hours (T4).  
Genomic DNA was collected at V0 to determine SMN2 copy number, and to assess the presence 
of the p.Gly287Arg variant of the SMN2 gene in the whole cohort. These data have already been 
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reported.[17] In the salbutamol arm, we also performed the genotype of the p.Arg16Gly variant 
of ADRB2, as previously reported.[18] 
 
 
Clinical and instrumental evaluation  
The following outcome measures were evaluated at each visit, except for V1: Forced Vital 
Capacity (FVC), Medical Research Council (MRC) score, North Star Ambulatory Assessment 
(NSAA), Six Minutes Walk Test (6MWT).[19-21] The muscle groups we have evaluated were 
previously described.[14] The last two evaluations were performed in ambulant patients only (11 
patients in salbutamol group and 11 in placebo group). We considered “clinical responders” 
salbutamol treated patients who had an increase in outcome measure scores above the median of 
placebo in at least two visits. NSAA discrete raw scores were transformed into linear measures, 
according to the Rasch model.[17] Muscle mass was assessed by Dual X-Ray Absorption (DXA) 
at V0, and V4.[22]  
 
Statistical analyses 
Mean and standard deviation (SD), and median and interquartile range (IQR) were calculated for 
continuous variables; proportions were used for categorical variables. Correlations of SMN2-fl, 
SMN-del7, SMN2-tot transcript levels, and SMN protein levels, with clinical characteristics were 
assessed by linear regression models. A multivariate model was used to evaluate the influence of 
other covariates. Due to the sample size and to the non-normal distribution of SMN2 transcript 
levels the non-parametric Kruskal–Wallis ‘ANOVA’ by ranks (KW) and Mann–Whitney U-test 
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(MW) were used.[19] The coefficient of variation (CV) was used to measure the longitudinal 
variation of SMN2 transcript levels over time.  
Clinical outcome measures at the different time points were compared by the signed and the 
signed rank test for paired samples. The variations at the different time points as a group were 





The study was approved by the Institutional Review Board of each participating Centre; a written 
informed consent was obtained from all subjects. The study was done in accordance with the 




Salbutamol is safe and well tolerated 
Forty-nine patients were screened and forty-five were enrolled between July 10th 2009 and 
September 9th 2010 (twenty-nine were males). The overall characteristics of the whole 
population at baseline have already been reported elsewhere, and will not be further 
discussed.[17] Twenty-three patients were randomized to the salbutamol and twenty-two to the 
placebo group (Fig. 1). At V0 the two groups were homogenous for demographic data and 
clinical assessments (Table 1). Nine patients did not complete the study, five in the salbutamol 
and four in the placebo arm. One patient of the salbutamol group dropped out before V4, due to a 
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skin erythema. The other patients withdrew from the study for personal or logistic issues, and not 
for adverse events.  
In general, salbutamol was well tolerated: occasionally, patients reported an increase of tremors, 
tachycardia, and/or cramps, that were transient and did not require specific treatment, nor 
interruption or reduction of salbutamol dosage. One patient of the placebo group reported 
transient tachycardia.  
No significant abnormalities in cardiologic assessments or laboratory tests were observed, with 
the exception of a statistically significant increase in serum CK levels in the salbutamol group 
(16/19 patients vs. 2/14 in the placebo arm), at V4 vs. V0 (p=0.0002 vs p=0.18, in salbutamol 
and placebo, respectively; Fig. 2).  
Table 1. Comparison of placebo and active compound patients at baseline  
 
 
Placebo Salbutamol p-value 
N 
patients 
Mean  Median Range SD 
N 
patients 
Mean  Median Range SD   
MALE 11         17           
FEMALE 11         6           
AGE (years) 22 34.71 37 18-55 11.41 23 35.39 34 21-53 11.04 0.83 
AMBULANT 11         11           
AGE AT ONSET 22 10.7 10 1-32 10.96 23 14.3 6 2-50 14.96 0.36 
DISEASE 
DURATION 
22 27.7 29 2-47 14.92 23 21 21 3-47 10.18 0.08 
MCR TOTAL 
SCORE 
22 61.4 58 25-89 17.36 23 59 60 34-82 14.6 0.68 
NSAA SCORE 11 21.6 25 7-31 85 11 17.5 18 7-23 5.28 0.19 
6MWT 
(meters) 












































22 72.17 65.14 
44.15-
138.92 























































Salbutamol increases SMN2 transcript levels 
In the placebo group, the longitudinal variation of SMN2 transcript levels was very low (mean 
CV+SD: 0.076+0.091, 0.173+0.117 for SMN2-fl, and SMN-del7, respectively), with no 
statistically significant differences across the different time points (p>0.09; Fig. 3-A, C); 
GAPDH transcript levels were more variable than those of SMN2 (mean CV+SD: 0.202+0.097, 
data not shown).  
In the salbutamol group we observed a progressive and statistically significant increase in SMN2-
fl levels only, from V0 through V4 (p<0.0001, Fig 3-B; SMN-del7, p=0.38, Fig. 3-D; SMN2-tot, 
p=0.10, data not shown). The ratio fl/del7 significantly increased with the treatment, particularly 
at V4 vs. V0 (p=0.02, data not shown). The number of patients responding to the treatment 
progressively increased from V0 to V4, achieving 100% at V4 (n=12/21, 13/20, and 15/15 at V2, 
V3, and V4, respectively; fig 4A). Regarding the mode of action of the compound, we observed 
unexpected mechanisms in a consistent proportion of samples (Fig. 4B). We observed a 
reduction of SMN2-tot transcript levels with an increase in the fl/del7 ratio in 19/56 (34%) 
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drawings (V2+V3+V4), and the opposite in 6/56 (10.7%), i.e. the increase in SMN2-tot transcript 
levels and the reduction in the fl/del7 ratio.  
At V2, only 50% of patients were early molecular responders. We tested whether this finding 
could be related to the beta2-adrenoceptor desensitization:  the ArgGly or GlyGly genotypes 
were more common among the early molecular responders, whereas 8/9 late molecular 
responders were Arg/Arg (OR=16,0; 95%CI=1.5-176.5; p=0.01).   
 
We then assessed SMN2 transcript level variations during the first hours after salbutamol 
assumption in two naïve type III SMA patients, who were not participating at the study. The first 
post-treatment sampling was performed after 30 minutes, when salbutamol raises therapeutic 
plasmatic concentrations.[23] In these two subjects, the molecular response was very similar to 
that observed in vitro and is summarized in fig. 5.[12] In patient 1 (Fig. 5A) SMN2-fl levels 
increase was about 65% after 30 minutes, SMN2-tot levels increased by 40-50% and the fl/del7 
ratio remained substantially stable. In patient 2 (Fig. 5B), we  observed a faster increase of about 
100% between 30 and 120 minutes; after 4 hours, SMN2-fl levels returned back to the baseline.   
Protein samples were not available for all drawings, due to insufficient blood amount or 
extraction failure. In the placebo group, we tested twenty-two, fourteen, and thirteen samples at 
V0, V2, and V3, respectively. In the salbutamol arm, we analysed twenty-one, fifteen, and 
thirteen samples, respectively. The CV ranged from 0.49 to 1.16 in the placebo group, and from 
0.66 to 0.82 in the salbutamol arm. The longitudinal variation of SMN protein levels was very 
wide in both groups, as shown in fig 6. Nonetheless, in the active compound group, we observed 
a trend towards a progressive increase in SMN levels, although non-significant (sign test, V2 and 
V3 vs. V0, p>0.149).  
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Exploratory evaluation of the clinical outcome  
The clinical outcome of salbutamol treatment was evaluated for possible correlations with the 
molecular response. We used a combination of different measures that were appropriate for the 
different levels of patients’ ability. The median variation of the individual clinical outcome 
measures in the placebo group was very low and not statistically significant over the different 
time points. In Supplemental Figure 1 (A, D, and G) the variations vs. V0 are represented: MRC 
(V2-V4 vs. V0, sign test p>0.92), NSAA (V2-V4 vs. V0, sign test p>0.96); 6MWT (V2-V4 vs. 
V0, sign test p>0.1). Among all items, 6MWT displayed the highest variability. 
All salbutamol-treated patients reported a subjective improvement in motor performance, due to 
a reduction of the perceived fatigability.  
While the global variation of the MRC score was not significant (Supplemental Fig. 1C), we 
identified a group of clinical responders who had a median improvement of 4 points (11/18, 
Supplemental Fig. 1B). The increase was statistically significant either by tests for paired 
samples (signed rank test p=0.001, V2-V4 vs V0), or by taking into account the MRC score 
variation at each time point vs. V0 (p=0.004, 0.03, 0.007 at V2, V3 and V4, respectively). 
In ambulant patients, the global variation of the NSAA score was not significant vs. V0 
(median= 2 points; interquartile range 4.0 and 6.0, at V3 and V4, respectively; Supplemental Fig. 
1F). Eight/eleven were clinical responders and had a significant increase at V3 and V4 vs. V0 
(median ≥ 3 points; signed rank test, p<0.042, Supplemental Fig. 1E); this improvement was also 




The 6MWT was performed by 10/11 ambulant patients: the missing patient did not agree to 
perform this assessment in other visits than V0. The median increase was of 27.85 and 30.41 
meters at V3 and V4, respectively (Mann-Withney U-test, p≥0.12; Supplemental Fig. 1I); in the 
eight clinical responders, the median increase was > 20.5 m (Supplemental Fig. 1H), and was 
statistically significant at V3 and V4 vs. V0 (signed rank test, p<0.037; data not shown).  
DXA was performed in 17/36 patients (seven of salbutamol group, ten of placebo); no 
differences were detected between V0 and V4 in both groups. We did not observe any difference 
in the respiratory function, as measured by spirometry: FVC value did not vary in the two groups 
after treatment (data not shown).   
We did not observe any correlation between increase in SMN2-fl transcript levels in salbutamol 




This is the first randomised placebo-controlled trial performed in adult type III SMA patients, 
designed to verify safety and tolerability of high dosages of salbutamol and to confirm the 
efficacy of the drug in increasing SMN2-fl transcripts. Our data show that salbutamol is well 
tolerated and safe, with no major side effects. The most severe adverse event was skin erythema 
in a patient who was not assuming other concomitant drugs. The undesired effect was probably 
related to salbutamol, even though it had occurred after over six months of therapy. The 
treatment was suspended and the skin erythema promptly remitted with steroids. 
The increase in serum CK levels, observed in treated patients, was not unexpected since it is not 
specific of SMA. HyperCKemia has been reported in asthmatic patients treated with salbutamol 
or other beta2-agonists.[25,26] A similar finding has been reported also in Kennedy’s disease 
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patients, treated with clenbuterol.[27] Further possible causes of hyper-CKemia in beta2-agonist 
treatment, include muscle injury, reduction in contraction efficiency due to lower calcium 
release, or cardiotoxic effect of these drugs.[26] All these mechanisms appear unlikely in our 
patients, since motor performance or cardiac function were not impaired.  
SMN2 transcript levels remained highly stable in blood over one year in the placebo group, 
indicating that spontaneous SMN2 mRNA level fluctuations are very tiny; accordingly, most 
treated patients showed a progressive and significant increase of the -fl isoform.  
The lack of response in half patients after three months of treatment was quite unexpected. Based 
on our in vitro data [12] and, more in general, on the receptor mediated mode of action of 
salbutamol, we expected to observe an early increase in SMN2 transcript levels in most or all 
patients. On the other hand, in the two naïve subjects we found a rapid increase in SMN2–fl 
levels about 30-60 minutes after the assumption of the compound, as expected on the basis of the 
pharmacokinetics of salbutamol. The lack of response at V2 in the late molecular responders 
could not be explained by the desensitization of the beta2-adrenoceptor, since 90% of these 
subjects had the Arg/Arg genotype. We hypothesize here that the regulation of SMN2 transcripts 
occurs according to a biphasic trend: a short-term transient response followed by a stable 
progressive long-term increase. Some open questions remain, such as whether this mode of 
action is specific of salbutamol or it is shared with other SMN2-active compounds, how does the 
long-term regulation occur, or whether this mode of response may impact the clinical outcome.     
In our hands, SMN protein dosage in leukocytes is less reproducible than the mRNA 
quantification. The few similar studies available in the literature had a cross-sectional design and 
did not provide longitudinal data on SMN protein variations.[16] The main issue in SMN protein 
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quantification might be related to the insoluble nature of the protein, that hampers the complete 
extraction from biological specimens.  
Regarding the exploratory analysis of the clinical outcome, the muscle performance remained 
stable in the placebo group, in accordance with other prospective longitudinal studies on SMA 
type II and III patients, showing a substantial stability of the disease over 1 year.[28-30]   
Even though the clinical effect of salbutamol was not striking, the significant improvement 
observed in the clinical responders may be ascribed to the effect of the compound.  The clinical 
efficacy could not be a primary endpoint of our study: a longer duration would have been 
required, due to the slow progression of the disease in type II-III adult patients.  Moreover, we 
should have designed a protocol including outcome measures more appropriate for adult SMA, 
such as the Expanded Hammersmith Functional Motor Scale, that are more sensitive to assess 
muscle strength and functional activity changes both in ambulant and non-ambulant patients. It is 
now available a map of measures more appropriate for SMA, as a result of an international 
consensus, that was not stated at the time our study was conceived.[31]   
Finally, and more importantly, very few salbutamol crosses the blood brain barrier (around 2% 
of the plasma concentration): the most part of the effect observed in the clinical responders is 
likely related to the enhancement of SMN2 expression in skeletal muscle, rather than in motor 
neurons. Indeed, beta-2 agonists have been shown to induce skeletal muscle hypertrophy and an 
increase in the stability of the muscle endplates;[32,33] it is unknown whether these effects could 
be mediated by the SMN pathway.  
Due to the limited permeability of the blood brain barrier, salbutamol is not suitable for the 
treatment of SMA today, but was the most promising at the time of study design. Actually, the 
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best treatment options for adult patients are still debated in the scientific community: the use of 
beta-2 agonists may help to preserve longer the motor function of adult chronic subjects up to the 
availability of more appropriate guidelines. Beta-2 agonists might be interesting candidates for 
the treatment of SMA if modified to cross the blood brain barrier.    
In conclusion, our data provide evidence that the dosage of SMN2 transcripts in peripheral blood 
can be usefully adopted as a pharmacodynamic marker for systemic therapies, aimed at 
increasing SMN expression. However, our study does not allow to establish whether SMN2 
transcript levels are a response biomarker for SMA. It is also possible that the restoration of 
SMN levels to normal range in blood does not necessarily correlate with the functional recovery, 
but might predict only the long-term effect of a given treatment. Studies on more clinically 
effective compounds, such as Risdiplam, could clarify whether the molecular response may 
predict the clinical outcome.[34] Finally, it is still unproven the utility of SMN-independent 
biomarkers, such as the SMA-MAP, a panel of plasma protein related with the clinical function 
of patients, or some miRNAs identified by others and ourselves.[35, 36 and unpublished data] 
These analytes might theoretically correlate better with patients’ outcome but have not yet been 
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Fig. 1. Scheme of study design. Patients were randomized 1:1 to salbutamol or placebo. 
   
Fig. 2. Salbutamol induces an increase in CPK levels. In the salbutamol group (n=19), we 
observed a statistically significant increase in serum CPK levels at V4 vs. V0 (Mood’s 
median test, p=0.0002). In placebo (n=14) the difference was not significant (p=0.18). The 
percent increase observed in salbutamol was statistically significant when compared with 




Fig. 3. Salbutamol induces an increase in SMN transcript levels. In the placebo group 
(A, C) the different SMN2 isoforms remained stable (mean CV+SD=0.076+0.091, and 
0.173+0.117, for SMN2-fl and –del7, respectively). In the salbutamol group SMN2-fl levels 
progressively increased (B, Kruskal–Wallis ‘ANOVA’ by ranks and Mann–Whitney U-test, 
V4 vs. V0, p<0.0001), differently from the -del7 isoform and SMN-tot (p=0.38 and p=0.10, 
respectively; D and data not shown). 
 
Fig. 4. The molecular response to salbutamol was different based at different time 
points. (A) After 3 months of  treatment, slightly more than 50% of patients showed an 
increase in SMN2-fl levels, beyond the experimental variability (early molecular 
responders). The number of molecular responders increased over time, up to 100% at 1 year. 
(B) Also the mode of response was variable. The different mechanisms are indicated.  
 
Fig. 5. Time-response curve to salbutamol in 2 different naïve patients. Two type III 
patients, who were not included in the study, were treated with salbutamol, up to 4 hrs. We 
observed a rapid increase in SMN2-fl levels, after 30 minutes from drug assumption, when 
the compound raises therapeutic concentrations in blood.  
 
Fig. 6. Longitudinal variation of SMN protein levels in placebo (A) and salbutamol (B) 
patients. SMN protein displayed a much wider variability compared to SMN transcript 
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levels. The levels were not significantly different at the different time points (signed-test V2 
and V3 vs V0, p>0.149). 
 
Supplemental Fig. 1. Effect of salbutamol treatment on clinical performance of 
patients. MRC scale score in placebo (A) salbutamol whole group treated (C) patients, (B) 
clinical responder subgroup. NSAA score in placebo (D) and whole group (F) treated 
patients, (E) clinical responder subgroup. 6-MWT in placebo (G) and salbutamol treated 
patients (I), (H) clinical responder subgroup. 
*statistically significant value (p<0.05). 
 
 
 
 
